168426 20260205155159.0 doi 10.1111/j.1365-2036.2007.03429.x sideral 81188 ART-2007-81188 eng Lanas, A Universidad de Zaragoza (orcid)0000-0001-5932-2889 Effects of long-term cyclo-oxygenase 2 selective and acid inhibition on Barrett's oesophagus 2007 Background: There is an overexpression of cyclo-oxygenase 2 (COX-2) in Barrett’s oesophagus (BO). Aim To determine the long-term effect of a COX-2 inhibitor on cellular mechanisms involved in BO. Methods: A randomized controlled trial was conducted in BO patients allocated to continue the usual proton pump inhibitor (PPI) alone treatment, or PPI combined with rofecoxib (25 mg/ day) for 6 months. Cell proliferation index and COX-2 expression in BO glands was determined in biopsy specimens at baseline and after treatment. Cell apoptosis, cyclin D1, p53 and vascular endothelial growth factor (VEGF) expression was also explored in a subset of patients. Student-t test and the U-Mann–Whitney test were used for quantitative and ordinal variables. Results: Of 62 patients, 58 completed the study. A higher proportion of patients on rofecoxib + PPI exhibited a decrease in COX-2 expression compared to those treated with PPI alone, but cell proliferation index was not affected. Unlike PPI alone, rofecoxib + PPI was associated with an increase in the apoptotic cell index, a decrease in p53 cell staining and VEGF expression in mucosal vessels. No effect on low-grade dysplasia or cyclin D1 was observed. Conclusions: The addition of rofecoxib to PPI therapy does not affect cell proliferation index in BO cells after 6 months of therapy, but does reduce COX-2 and VEGF expression and increases cell apoptosis. info:eu-repo/semantics/closedAccess All rights reserved http://www.europeana.eu/rights/rr-f/ 3.201 2007 PHARMACOLOGY & PHARMACY 55 / 203 = 0.271 2007 Q2 T1 GASTROENTEROLOGY & HEPATOLOGY 16 / 50 = 0.32 2007 Q2 T1 info:eu-repo/semantics/article info:eu-repo/semantics/publishedVersion Ortego, J Universidad de Zaragoza (orcid)0000-0002-3869-8235 Sopeña, F Universidad de Zaragoza (orcid)0000-0002-8678-4680 Alcedo, J (orcid)0000-0001-6522-6682 Barrio, E (orcid)0000-0001-5603-3045 Bujanda, L Cosme, A Bajador, E Universidad de Zaragoza (orcid)0000-0002-1732-2941 Parra-Blanco, A Ferrandez, A (orcid)0000-0003-2280-9372 Piazuelo, E (orcid)0000-0001-5813-3445 Quintero, E Pique, JM 1007 610 Universidad de Zaragoza Dpto. Medicina, Psiqu. y Derm. Area Medicina 1000 020 Universidad de Zaragoza Dpto. Anat.Pat.Med.Leg.For.To. Area Anatomía Patológica 26, 6 (2007), 913-923 Aliment. pharmacol. ther. ALIMENTARY PHARMACOLOGY & THERAPEUTICS 0269-2813 1187572 http://zaguan.unizar.es/record/168426/files/texto_completo.pdf Versión publicada 1842132 http://zaguan.unizar.es/record/168426/files/texto_completo.jpg?subformat=icon icon Versión publicada oai:zaguan.unizar.es:168426 articulos driver 2026-02-05-14:36:19 ARTICLE